Future of Evidence and Smart Health Conference
Session 10: What might the future of evidence generation and use look like?
Thomas Brookland, MSc
- Personalised Healthcare Policy Strategy Leader
- F. Hoffmann-La Roche Ltd., Switzerland
Increasing interest and excitement in the potential of health data and evidence within the healthcare community has been triggered by a number of developments, including the greater availability and quality of electronic healthcare information, the emergence of tools for advanced analysis of large data volumes (greater computing power, data handling and analysis techniques) and the ability to link data from multiple sources.
There are a multitude of European initiatives and projects ongoing in this data and evidence generation space, a number of which are being driven by the European Institutions and Regulatory bodies. However, the scope and objectives of these projects often seem to be framed within the next 3 – 5 years, with numerous goals citing 2025 as a target date.
This final session of the workshop will take a look at data and evidence generation a little further into the future and ask what might this space look like in the next 10 – 15 years time and what opportunities, challenges and policy implications may come with this that we should already be thinking about now.
Panel Discussion and Q&A
Alison Cave, PhD
- Chief Safety Officer
- Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
Cécile Mathilde Ollivier, MS
- OCM Director - Regulatory Science Europe
- Critical Path Institute (C-Path), Netherlands
Irene Nunes, PhD
- VP, Head of Regulatory Affairs
- Flatiron Health, United States
Frank Petavy, MS
- Head of Methodology
- European Medicines Agency, Netherlands
Jesper Kjær, MS
- Head of Danish Medicines Agency’s Data Analytics Centre
- Danish Medicines Agency (DKMA), Denmark